- Report
- March 2025
- 289 Pages
Global
From €5345EUR$5,600USD£4,478GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- May 2024
- 134 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- May 2024
- 137 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- June 2022
- 118 Pages
Global
From €4533EUR$4,750USD£3,798GBP
Pericarditis is a condition that affects the pericardium, the thin sac that surrounds the heart. It is usually caused by a viral infection, but can also be caused by other conditions such as autoimmune diseases, radiation therapy, or trauma. Treatment for pericarditis typically involves anti-inflammatory medications, such as non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Other medications, such as colchicine, may also be used to reduce inflammation.
The pericarditis drug market is a subset of the larger cardiovascular drug market. It is composed of medications used to treat pericarditis, such as NSAIDs, corticosteroids, and colchicine. These drugs are used to reduce inflammation and pain associated with the condition.
Some of the companies in the pericarditis drug market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. These companies produce a variety of medications used to treat pericarditis, including NSAIDs, corticosteroids, and colchicine. Show Less Read more